TY - JOUR
T1 - Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma
T2 - A single institution phase II study
AU - Uy, G. L.
AU - Goyal, S. D.
AU - Fisher, N. M.
AU - Oza, A. Y.
AU - Tomasson, M. H.
AU - Stockerl-Goldstein, K.
AU - DiPersio, J. F.
AU - Vij, R.
PY - 2009
Y1 - 2009
N2 - The appropriate induction therapy before and the role of maintenance therapy after auto-SCT for patients with multiple myeloma remain areas of active investigation. We conducted a study in 40 patients with bortezomib given sequentially pre-auto-SCT and as maintenance therapy post auto-SCT. Pre-transplant bortezomib was administered for two cycles followed by high-dose melphalan 200 mg/m2 with auto-SCT of G-CSF-mobilized PBMCs. Post transplant bortezomib was administered weekly for 5 out of 6 weeks for six cycles. No adverse effects were observed on stem cell mobilization or engraftment. An overall response rate of 83% with a CR+very good partial remission (VGPR) of 50% was observed with this approach. Three-year Kaplan-Meier estimates of disease-free survival and overall survival (OS) were 38.2 and 63.1%, respectively. Bortezomib reduced CD8+ cytotoxic T cell and CD56+ natural killer cell PBL subsets and was clinically associated with high rates of viral reactivation to varicella zoster.
AB - The appropriate induction therapy before and the role of maintenance therapy after auto-SCT for patients with multiple myeloma remain areas of active investigation. We conducted a study in 40 patients with bortezomib given sequentially pre-auto-SCT and as maintenance therapy post auto-SCT. Pre-transplant bortezomib was administered for two cycles followed by high-dose melphalan 200 mg/m2 with auto-SCT of G-CSF-mobilized PBMCs. Post transplant bortezomib was administered weekly for 5 out of 6 weeks for six cycles. No adverse effects were observed on stem cell mobilization or engraftment. An overall response rate of 83% with a CR+very good partial remission (VGPR) of 50% was observed with this approach. Three-year Kaplan-Meier estimates of disease-free survival and overall survival (OS) were 38.2 and 63.1%, respectively. Bortezomib reduced CD8+ cytotoxic T cell and CD56+ natural killer cell PBL subsets and was clinically associated with high rates of viral reactivation to varicella zoster.
UR - http://www.scopus.com/inward/record.url?scp=67349269915&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.384
DO - 10.1038/bmt.2008.384
M3 - Article
C2 - 19029964
AN - SCOPUS:67349269915
SN - 0268-3369
VL - 43
SP - 793
EP - 800
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 10
ER -